



# 2021 Taipei International Breast Cancer Symposium

## 台北國際乳癌研討會

---

### **The progress of antibody drug conjugate treatment for HER2 positive breast cancer**

Shanu Modi, M.D.

Member, Breast Medicine Service,  
Memorial Sloan Kettering Cancer Center

Associate Professor,  
Weill Cornell Medical College  
New York, NY, U.S.A.

Antibody–drug conjugates (ADCs) are a unique class of anticancer agents, which combine the specificity of monoclonal antibodies toward cellular-antigens with the targeted release of potent cytotoxic drugs, allowing for the potential of increased anticancer efficacy and reduced toxicity compared with traditional chemotherapies. Trastuzumab emtansine (T-DM1) is the prototype ADC for HER2+ breast cancer and has been widely adopted as a standard therapy for the treatment of patients with advanced stage or metastatic disease after progression on first line therapy.

Advances in synthetic biochemistry methods in monoclonal antibody production, linker technology and novel payload discovery have ushered in a new generation of ADCs with potentially improved tissue specificity and cytotoxicity relative to the previous agents. Many of these new drugs exhibit impressive activity against treatment-refractory cancers.

The aim of this presentation is to review the efficacy and safety of current and emerging ADCs for HER2+ metastatic breast cancer (MBC).